Table 1.
Clinical and treatment features of patients with pulmonary mycobacterial disease
| Patient groups | |||||
|---|---|---|---|---|---|
| Variable | Category | NR-TB | MDR | NTM | Total |
| Sex | Male | 58 (42·0) | 60 (43·5) | 20(14·5) | 138 (100) |
| Female | 27 (38·0) | 34 (47·9) | 10 (14·1) | 71 (100) | |
| Median age, years (s.d.) | 32 (13·8) | 38 (11·3) | 49 (13·6) | 40 (13·7) | |
| Median number of drugs (s.d.) | 3 (0·1)* | 4 (0·6)† | 3 (0·7)‡ | 3 (0·8) | |
| Median disease duration, days (s.d.) | 109 (101·6) | 371 (612·8)ψ | 630 (1149·6)# | 384 (889) | |
| Pathogen | M. tuberculosis | 85 (47·5) | 94 (52·5) | – | 179 (100) |
| M. abscessus | – | – | 6 (100) | 6 (100) | |
| M. kansasii | – | – | 6 (100) | 6 (100) | |
| M. avium | – | – | 5 (100) | 5 (100) | |
| M. fortuitum | – | – | 4 (100) | 4 (100) | |
| M. intracelulare | – | – | 3 (100) | 3 (100) | |
| M. asiaticum | – | – | 1 (100) | 1 (100) | |
| M. lentiflavum | – | – | 1 (100) | 1 (100) | |
| Ign | – | – | 4 (100) | 4 (100) | |
| Cavitation | Yes | 17 (22·7) | 35 (46·7) | 23 (30·6) | 75 (100) |
| No | 45 (43·7) | 51(49·5) | 7 (6·8) | 103 (100) | |
| Ign | 23 (74·2) | 8 (25·8) | 0 | 31 (100) | |
Most important drug regimen:
*
isoniazid (H) + rifampicin (R) + pyrazinamide (PZ), 2 months and H + R, 4 months;
†
amikacin (AM) + ethambutol(E) + ofloxacin (OFX) + terizidone (TZ);
‡
clarithromycin (CLA) + E + TZ and E + H + R.
ψ
P < 0·05 in relation to active non-resistant tuberculosis (NR-TB) and non-tuberculous mycobacteria (NTM) groups;
#
P < 0·05 in relation to NR-TB and multi-drug-resistant TB (MDR-TB). Ign = data could not be determined. Median (s.d.): median (standard deviation).